Carfilnat 60 mg contains Carfilzomib, a next-generation proteasome inhibitor used mainly in the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow.
Administered as an intravenous infusion, Carfilnat works by disrupting protein recycling within cancer cells, causing them to die.
This targeted approach has provided a valuable option for patients, especially those whose disease has come back after other treatments.

Mechanism of Action

Carfilzomib specifically inhibits the chymotrypsin-like activity of the 20S proteasome, a protein complex inside cells that breaks down unneeded or damaged proteins.

• By blocking the proteasome, carfilzomib causes a buildup of these proteins inside myeloma cells.

• This stresses and disrupts important cellular functions, ultimately triggering cell death (apoptosis).

  Uses / Indications

  Carfilnat is used for:

  • Relapsed or refractory multiple myeloma, usually in combination with other agents like dexamethasone or lenalidomide.

  • It may be used after patients have already received treatments with drugs like bortezomib and immunomodulators.

    Adverse Effects

    Because it disrupts a core cellular process, carfilzomib has side effects that need careful monitoring.

    Common side effects include:

    • Fatigue, low appetite, anaemia.

    • Mild nausea, diarrhoea or constipation.

    • Low blood counts (white cells and platelets) increasing infection and bleeding risks.

    Important but less common side effects:

    • Heart-related issues: shortness of breath, high blood pressure, heart failure, or irregular heartbeat. Your doctor may do echocardiograms before and during treatment.